Kineta Long Term Debt 2014-2024 | KANT
Kineta long term debt from 2014 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Kineta Annual Long Term Debt
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$1 |
| 2021 |
$10 |
| 2020 |
$13 |
| 2019 |
$15 |
| 2018 |
$ |
| 2017 |
$ |
| 2016 |
$ |
| 2015 |
$ |
| 2014 |
$10 |
| 2013 |
$ |
Kineta Quarterly Long Term Debt
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
$10 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
$10 |
| 2021-03-31 |
$11 |
| 2020-12-31 |
$13 |
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$15 |
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
$10 |
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
